The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 26, 2023

Filed:

Oct. 05, 2021
Applicant:

Somerset Therapeutics, Llc, Hollywood, FL (US);

Inventors:

Mandar V. Shah, Rockaway, NJ (US);

Ilango Subramanian, Warren, NJ (US);

Veerappan Subramanian, Warren, NJ (US);

Aman Trehan, Hillsborough, NJ (US);

Assignee:

Somerset Therapeutics, LLC, Hollywood, FL (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/542 (2006.01); A61K 31/498 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 9/08 (2006.01); A61K 47/32 (2006.01); A61K 47/34 (2017.01);
U.S. Cl.
CPC ...
A61K 31/542 (2013.01); A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 31/498 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/186 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01);
Abstract

Disclosed herein are pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. In aspects, the invention provides compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s). In facets, compositions comprise a penetration enhancer component comprising one or more penetration enhancer compound(s)/molecule(s). In aspects, the invention provides compositions comprising effective amounts of brimonidine compound(s) and brinzolamide compound(s) capable of being administered once or twice daily for the treatment of elevated intraocular pressure, but which provide similar efficacy to a similar or substantially identical reference product requiring administration three times per day. In facets, the invention provides compositions capable of being administered at a frequency resulting in providing a lower total dose of both brinzolamide and brimonidine compound(s) to a recipient, but nonetheless are as or more effective in IOP control as such similar or substantially identical reference products.


Find Patent Forward Citations

Loading…